Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ioanna Mavrommati
Observed names:
I. Mavrommati,
Mavrommati, Ioanna
Institutions:
Institute of Cancer Research,
Breast Cancer Now
Observed institutions:
University of London,
Institute of Cancer Research,
Queen Mary University of London,
Breast Cancer Now,
Cancer Research UK,
University of Oxford,
Institute of Cancer Research,
CRUK/MRC Oxford Institute for Radiation Oncology,
Blizard Institute,
Medical Research Council
show all 10
ORCID:
0000-0002-5436-2619
Observed ORCID:
0000-0002-5436-2619
OpenAlex ID:
A5064639228
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
2015
·
Sophia X. Pfister
, Enni Markkanen
, et al.
·
Cancer Cell
·
340
GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine
2018
·
R. Ferro
, A. Adamska
, et al.
·
Oncogene
·
123
Subclonal heterogeneity and evolution in breast cancer
2021
·
Ioanna Mavrommati
, Flora Johnson
, et al.
·
npj Breast Cancer
·
64
PDF
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response
2023
·
Philip Bland
, Harry Saville
, et al.
·
Nature Genetics
·
49
PDF
-TrCP and Casein Kinase III Mediated Degradation of Cyclin F Controls Timely Mitotic Entry
2018
·
Ioanna Mavrommati
, Roberta Faedda
, et al.
·
Cell Reports
·
44
PDF
Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion
2016
·
Ioanna Mavrommati
, Ouma Cisse
, et al.
·
Scientific Reports
·
37
PDF
Class II Phosphoinositide 3-Kinases Contribute to Endothelial Cells Morphogenesis
2013
·
Gianpaolo Tibolla
, Roberto Piñeiro
, et al.
·
PLoS ONE
·
34
PDF
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer
2021
·
Barrie Peck
, Philip Bland
, et al.
·
Cancer Research
·
24
PDF
Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth
2019
·
Ouma Cisse
, Muzthahid Quraishi
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
22
PDF
mTOR Inhibitors: Facing New Challenges Ahead
2011
·
I. Mavrommati
, T. Maffucci
·
Current Medicinal Chemistry
·
8
Co-occurrence of transcriptionally distinct persister cell states underpins neoadjuvant therapy resistance in triple‑negative breast cancer
2026
·
Yu Zhang
, Fatemeh Ahmadi Moughari
, et al.
·
Genome Medicine
·
2
Tracing the evolutionary trajectory of CDK4/6 inhibitor resistance in oestrogen receptor positive breast cancer
2025
·
Rachael Natrajan
, Ioanna Mavrommati
, et al.
·
Research Square
·
1
PDF
Abstract PO4-13-11: Epigenetically defined sub-clonal heterogeneity drives therapy resistance in triple-negative breast cancer
2024
·
Fatemeh Ahmadimoghari
, Yu Zhang
, et al.
·
Cancer Research
·
1
The anion channel GPR89 is a tumor-specific dependency in breast cancer
2026
·
Riccardo Ferro
, Alexandra Carroll
, et al.
·
Nature Communications
PDF
Co-occurrence of transcriptionally distinct persister cell states underpins neoadjuvant therapy resistance in triple‑negative breast cancer
2026
·
Zhang, Yu
, Moughari, Fatemeh Ahmadi
, et al.
·
Figshare
Inference of Cancer Drug Cross Resistance Using Only Single-Drug Exposure Data
2026
·
Frederick J.H. Whiting
, Ioanna Mavrommati
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
Abstract B058: Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
2024
·
Ioanna Mavrommati
, Fatemeh Ahmadi Moughari
, et al.
·
Cancer Research
Abstract B020: SF3B1 hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response
2023
·
Philip Bland
, Harry Saville
, et al.
·
Molecular Cancer Therapeutics
Data from 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer
2023
·
Barrie Peck
, Philip Bland
, et al.
Supplementary Methods from 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer
2023
·
Barrie Peck
, Philip Bland
, et al.
PDF
Table S1 from 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer
2023
·
Barrie Peck
, Philip Bland
, et al.
Figure S1- S8 from 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer
2023
·
Barrie Peck
, Philip Bland
, et al.
Table S2 from 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer
2023
·
Barrie Peck
, Philip Bland
, et al.
Table S3 from 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer
2023
·
Barrie Peck
, Philip Bland
, et al.
Table S5 from 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer
2023
·
Barrie Peck
, Philip Bland
, et al.
Show more works
View as search
Works count:
44
Citation count:
750
H-index:
9
I10-index:
9
Year
Topic
Type